Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials

BACKGROUND: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) >18 months. PATIENTS AND METHODS: A retrospective analysis of data from 57...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Genitourin Cancer
Autori principali: Tannir, Nizar M., Figlin, Robert A., Gore, Martin E., Michaelson, M. Dror, Motzer, Robert J., Porta, Camillo, Rini, Brian I., Hoang, Caroline, Lin, Xun, Escudier, Bernard
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736765/
https://ncbi.nlm.nih.gov/pubmed/28711490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.06.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi